MA27626A1 - Nouveaux derives de 2-pyridinecarboxamide - Google Patents

Nouveaux derives de 2-pyridinecarboxamide

Info

Publication number
MA27626A1
MA27626A1 MA28455A MA28455A MA27626A1 MA 27626 A1 MA27626 A1 MA 27626A1 MA 28455 A MA28455 A MA 28455A MA 28455 A MA28455 A MA 28455A MA 27626 A1 MA27626 A1 MA 27626A1
Authority
MA
Morocco
Prior art keywords
atom
formula
elements
group
oxygen
Prior art date
Application number
MA28455A
Other languages
English (en)
Inventor
Teruyuki Nishimura
Jun-Ichi Eiki
Morihiro Mitsuya
Makoto Bamba
Fumiko Sakai
Hitomi Watanabe
Yasuhiro Sasaki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA27626A1 publication Critical patent/MA27626A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé qui a un effet activateur de la glucokinase et est utile comme agent thérapeutique contre le diabète sucré, étant représenté par une formule (I): [dans laquelle X1 représente un atome d'azote, atome de soufre, atome d'oxygène ou ceux semblables; R1 représente un groupement aryle de 6 à 10 éléments, groupement hétéroaryle de 5 à 7 éléments ou ceux semblables; D représente un atome d'oxygène ou atome de soufre; R2 et R3 sont les mêmes ou différents, chacun représentant un atome d'hydrogène, groupement alkyle inférieur ou ceux semblables; une formule (II) représente un groupement hétéroaryle facultativement substitué de 5 à 7 éléments ou ceux semblables; une formule (III) représente un groupement monocyclique ou bicyclique] ou un sel pharmaceutiquement acceptable de celui-ci.
MA28455A 2003-02-13 2005-08-24 Nouveaux derives de 2-pyridinecarboxamide MA27626A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034987 2003-02-13
JP2003342860 2003-10-01
JP2004014799 2004-01-22

Publications (1)

Publication Number Publication Date
MA27626A1 true MA27626A1 (fr) 2005-11-01

Family

ID=32995582

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28455A MA27626A1 (fr) 2003-02-13 2005-08-24 Nouveaux derives de 2-pyridinecarboxamide

Country Status (21)

Country Link
US (3) US7629362B2 (fr)
EP (1) EP1598349B1 (fr)
JP (1) JP4400563B2 (fr)
KR (1) KR20050101208A (fr)
AR (1) AR045414A1 (fr)
AT (1) ATE517887T1 (fr)
AU (2) AU2004220234C1 (fr)
BR (1) BRPI0407283A (fr)
CA (1) CA2515841C (fr)
EC (1) ECSP056016A (fr)
HK (1) HK1088602A1 (fr)
IL (1) IL169905A0 (fr)
MA (1) MA27626A1 (fr)
MX (1) MXPA05008619A (fr)
NO (1) NO20054224L (fr)
NZ (1) NZ540791A (fr)
PE (1) PE20050194A1 (fr)
TW (1) TWI336329B (fr)
UA (1) UA82867C2 (fr)
WO (1) WO2004081001A1 (fr)
ZA (1) ZA200504852B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN1703408A (zh) 2002-10-03 2005-11-30 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑－2－基)酰胺或磺酰胺
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
ATE517887T1 (de) * 2003-02-13 2011-08-15 Msd Kk Neue 2-pyridincarbonsäureamidderivate
RU2329261C2 (ru) * 2003-12-29 2008-07-20 Баниу Фармасьютикал Ко., Лтд. Новое 2-гетероарил-замещенное производное бензимидазола
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20070149547A1 (en) * 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP4700684B2 (ja) 2004-04-02 2011-06-15 ノバルティス アーゲー ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
EP1737870A1 (fr) 2004-04-02 2007-01-03 Novartis AG Derives thiazolopyridine, compositions pharmaceutiques les contenant et procedes de traitement de troubles a mediation par glucokinase
AU2005290413A1 (en) * 2004-10-08 2006-04-13 Banyu Pharmaceutical Co., Ltd. Method for producing thioether compound
JP5036316B2 (ja) 2004-11-02 2012-09-26 Ｍｓｄ株式会社 アリールオキシ置換ベンズイミダゾール誘導体
BRPI0607433A2 (pt) * 2005-02-25 2009-09-08 Takeda Pharmaceutical composto ou um sal do mesmo, pró-droga, agente farmacêutico, inibidor de peptidase, uso de um composto ou de uma pró-droga do mesmo, e, métodos de prevenção ou tratamento de doenças, de inibição de peptidase em um mamìfero, e de produção de um composto
BRPI0607583A2 (pt) 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
ATE466003T1 (de) 2005-08-05 2010-05-15 Bristol Myers Squibb Co Herstellung von 2-aminothiazol-5- carbonsäurederivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
JP4990783B2 (ja) * 2005-09-30 2012-08-01 Ｍｓｄ株式会社 ２−ヘテロアリール置換インドール誘導体
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
AU2006298727B2 (en) 2005-10-05 2011-11-17 F. Hoffmann-La Roche Ag Naphthyridin derivatives
CA2628274A1 (fr) * 2005-11-01 2007-05-10 Array Biopharma Inc. Activateurs de glucokinase
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
ES2536547T3 (es) * 2006-03-24 2015-05-26 Array Biopharma, Inc. Análogos de 2-aminopiridina como activadores de glucoquinasa
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
AU2007278261A1 (en) * 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
CA2665195C (fr) * 2006-10-11 2011-08-09 Amgen Inc. Composes d'imidazo- et de triazolo-pyridine et leurs procedes d'utilisation
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
JP5207981B2 (ja) 2007-01-10 2013-06-12 田辺三菱製薬株式会社 ヒドラゾン誘導体
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
JP5450108B2 (ja) * 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
WO2008156174A1 (fr) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. Composé de pyrazinamide
EP2020232A1 (fr) * 2007-08-03 2009-02-04 Zeltia, S.A. Dérives de N-(1-thiazolyl)-amide pour traiter l'obésité, le diabète et des maladies cardiovasculaires
EA019104B1 (ru) * 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2217591A4 (fr) * 2007-11-06 2011-10-26 Astrazeneca Ab Certains dérivés de 2-pyrazinone et leur utilisation comme inhibiteurs d'élastase des neutrophiles
US8232284B2 (en) 2007-11-12 2012-07-31 Msd K. K. Heteroaryloxy quinazoline derivative
JPWO2009081782A1 (ja) 2007-12-25 2011-05-06 萬有製薬株式会社 Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体
WO2009083553A1 (fr) * 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
JP2011513253A (ja) * 2008-02-27 2011-04-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病を治療するためのカルボキサミド−ヘテロアリール誘導体
WO2009113637A1 (fr) * 2008-03-12 2009-09-17 東ソー株式会社 Nouveau dérivé de thiazole, matrice ayant un dérivé de thiazole immobilisé sur celle-ci, procédé de fabrication du dérivé de thiazole et procédé de fabrication de la matrice
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
AU2009285194A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co.,Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
AU2009290474A1 (en) 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
WO2010056717A1 (fr) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Amines bicycliques substituées pour le traitement du diabète
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
SI2406253T1 (sl) 2009-03-11 2013-09-30 Pfizer Inc. Derivati benzofuranila, uporabljeni kot inhibitorji glukokinaze
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2771190C (fr) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser
MX2012005994A (es) 2009-12-04 2012-08-08 Taisho Pharmaceutical Co Ltd Compuestos de 2-piridona.
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
CA2870488A1 (fr) 2012-04-16 2013-10-24 Kaneq Pharma Inc. Derives de phosphonates aromatiques fusionnes utilises comme precurseurs d'inhibiteurs de ptp-1b
US9527838B2 (en) 2012-12-17 2016-12-27 Merck Sharp & Dohme Corp. 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
SG11201609336PA (en) 2014-05-13 2016-12-29 Sloan Kettering Inst Cancer Hsp70 modulators and methods for making and using the same
WO2022146755A1 (fr) * 2020-12-29 2022-07-07 Merck Sharp & Dohme Corp. Composés pyridyle amido-substitués et leurs méthodes d'utilisation pour le traitement des virus de l'herpès

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
JPS58121215A (ja) 1982-01-14 1983-07-19 Tanabe Seiyaku Co Ltd 抗アレルギ−剤
CH680582A5 (fr) 1991-04-23 1992-09-30 Supermatic Kunststoff Ag
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
JP4723059B2 (ja) 2000-08-03 2011-07-13 帝人化成株式会社 難燃性熱可塑性樹脂組成物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2002952839A0 (en) 2002-11-21 2002-12-05 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
ATE517887T1 (de) 2003-02-13 2011-08-15 Msd Kk Neue 2-pyridincarbonsäureamidderivate
CN101712657A (zh) * 2003-02-26 2010-05-26 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
JP2007523142A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ ベンズアミド誘導体、およびグルコキナーゼ活性化物質としてのそれらの使用
CA2554686A1 (fr) 2004-02-18 2005-09-01 Astrazeneca Ab Composes
AU2005290413A1 (en) 2004-10-08 2006-04-13 Banyu Pharmaceutical Co., Ltd. Method for producing thioether compound
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.

Also Published As

Publication number Publication date
AR045414A1 (es) 2005-10-26
TWI336329B (en) 2011-01-21
PE20050194A1 (es) 2005-04-23
KR20050101208A (ko) 2005-10-20
ZA200504852B (en) 2006-05-31
AU2004220234C1 (en) 2013-01-17
AU2004220234A1 (en) 2004-09-23
NZ540791A (en) 2009-09-25
HK1088602A1 (en) 2006-11-10
CA2515841C (fr) 2010-06-01
JPWO2004081001A1 (ja) 2006-06-08
ECSP056016A (es) 2006-01-27
NO20054224L (no) 2005-11-10
US20060258701A1 (en) 2006-11-16
US7629362B2 (en) 2009-12-08
EP1598349A4 (fr) 2008-12-31
EP1598349B1 (fr) 2011-07-27
EP1598349A1 (fr) 2005-11-23
ATE517887T1 (de) 2011-08-15
US8765789B2 (en) 2014-07-01
WO2004081001A1 (fr) 2004-09-23
IL169905A0 (en) 2007-07-04
NO20054224D0 (no) 2005-09-12
US8344003B2 (en) 2013-01-01
AU2004220234B2 (en) 2009-11-26
UA82867C2 (en) 2008-05-26
BRPI0407283A (pt) 2006-01-31
AU2010200004B2 (en) 2012-07-19
AU2010200004A1 (en) 2010-01-28
CA2515841A1 (fr) 2004-09-23
JP4400563B2 (ja) 2010-01-20
US20100041660A1 (en) 2010-02-18
MXPA05008619A (es) 2005-11-04
TW200510381A (en) 2005-03-16
US20130085156A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
MA27626A1 (fr) Nouveaux derives de 2-pyridinecarboxamide
BRPI0413232A (pt) novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
DK0612321T3 (da) Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet
DE60236851D1 (en) Pyrimidinmatrixmetalloproteinaseinhibitoren
MA28973B1 (fr) Compose heterocyclique fusionne
MA29773B1 (fr) Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acides
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
HUP0004531A2 (hu) VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
EA200000096A1 (ru) Производные арилоксиарилсульфониламиногидроксамовой кислоты
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
RU94016183A (ru) Производные пиперазина
EP1259487B8 (fr) Derives de 2-amino-nicotinamide et leur utilisation comme inhibiteurs de tyrosine kinase du recepteur vegf
DE69514367T2 (de) Substituierte amidderivate
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA30029B1 (fr) Derives spiro aza-substitue
MA30524B1 (fr) Agent de lutte antiparasite contenant un nouveau derive de pyridyl-methanamine ou un sel de celui-ci
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
ATE266022T1 (de) Imidazol derivate als raf kinase inhibitoren
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB